Table 1 Demographic and clinical characteristics of the baseline study cohort (n = 87)

Age (yrs), median (IQR)

79.3 (70.7–84.8)

Sex M, n (%)

45 (51.7)

Current Smokers, n (%)

14 (16.1)

Hyperlipidemia, n (%)

48 (55.2)

Heart Failure, n (%)

18 (20.7)

Atrial Fibrillation, n (%)

28 (32.2)

Diabetes, n (%)

11 (12.6)

Hypertension, n (%)

21 (24.1)

Blood Brain Barrier Disruption, n (%)

37 (42.5)

Cerebral Edema, n (%)

34 (39.1)

Relevant HT*, n (%)

15 (17.2)

3-month Modified Rankin Scale > 2, n (%)

41 (47.1)

Acute Ischemic Stroke Treatments

 Systemic Thrombolysis

36 (41.4)

 Endovascular Thrombectomy

26 (29.9)

 Endovascular Thrombectomy with Systemic Thrombolysis

25 (28.7)

Stroke Treatment Latency (min), median (IQR)

155 (120–293)

NIH Stroke Scale, median (IQR)

17 (11–22)

Lipid-Lowering Medications, n (%)

31 (35.6)

Corticosteroids, n (%)

2 (2.3)